CYP2D6 predicted metabolizer status and safety in adult patients with attention‐deficit hyperactivity disorder participating in a large placebo‐controlled atomoxetine maintenance of response clinical trial. (14th June 2015)

• Record Type: Journal Article
• Authors: Fijal, Bonnie A.; Guo, Yingying; Li, Si G.; Ahl, Jonna; Goto, Taro; Tanaka, Yoko; Nisenbaum, Laura K.; Upadhyaya, Himanshu P.
• Is Part Of: Journal of clinical pharmacology. Volume 55:Number 10(2015:Oct.)
• Page Start: 1167
• Page End: 1174
• Publication Date: 2015-06-14
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.530
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph530-sec-0001" sec-type="section"> <p>Atomoxetine, which is indicated for treatment of attention‐deficit hyperactivity disorder (ADHD), is predominantly metabolized by genetically polymorphic cytochrome P450 2D6 (CYP2D6). Based on identified <italic>CYP2D6</italic> genotypes, individuals can be categorized into 4 phenotypic metabolizer groups as ultrarapid, extensive, intermediate, and poor. Previous studies have focused on observed differences between poor and extensive metabolizers, but it is not well understood whether the safety profile of intermediate metabolizers differs from that of ultrarapid and extensive metabolizers. This study compared safety and tolerability among the different CYP2D6 metabolizer groups in the 12‐week open‐label phase of an atomoxetine study in adult patients with ADHD. Genotyping identified 1039 patients as extensive/ultrarapid metabolizers, 780 patients as intermediate metabolizers, and 117 patients as poor metabolizers. Common (≥5% frequency) treatment‐emergent adverse events did not significantly differ between extensive/ultrarapid and intermediate metabolizers (odds ratios were <2.0 or >0.5). Poor metabolizers had higher frequencies of dry mouth, erectile dysfunction, hyperhidrosis, insomnia, and urinary retention compared with the other metabolizer groups. There were no significant differences between extensive/ultrarapid and intermediate metabolizers in changes from baseline in vital signs. These results suggest that data from CYP2D6 intermediate and extensive/ultrarapid metabolizers can be combined when considering safety analyses related to atomoxetine.</p> </sec> </abstract>